Treatment for CD5+ B cell lymphoma
Assignee3M Innovative Properties Company
InventorsRichard L. Miller, David E. Spaner
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for increasing expression of cell surface molecules of CD5+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and/or TLR8.
Claims4
A method of treating a subject with a CD5+ B cell lymphoma, the method comprising administering to the subject an IRM,
- wherein the IRM is
- 4-amino-2-(ethoxymethyl)-α,α-dimethyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinoline-1-ethanol;
- 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine;
- or
- N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide.
Dependencies are inferred from the claim text.